Sotorasib in KRAS G12C-Mutated Advanced Pancreatic Cancer: CodeBreaK 100 Trial
Medical Supporter — Avis d’information
Cet article est une synthèse d’informations médicales internationales et ne constitue pas un avis médical ; il ne remplace pas le diagnostic ni le plan de traitement de votre médecin traitant. Les informations présentées sont compilées à partir de publications publiques et de déclarations officielles d’établissements médicaux japonais ; l’adéquation et les résultats de toute thérapie varient selon chaque patient et doivent être évalués individuellement par un médecin qualifié.
On December 21, 2022, Dr. John H. Strickler and colleagues published the results of the CodeBreaK 100 Phase 1/2 clinical trial in The New England Journal of Medicine. This study evaluated the efficacy and safety of Sotorasib (Lumakras), a first-in-class KRAS G12C inhibitor, in patients with heavily pretreated advanced pancreatic cancer harboring the KRAS G12C mutation.
Study Design: CodeBreaK 100 Trial
The trial included 38 patients with KRAS G12C-mutated pancreatic cancer who had progressed on prior systemic therapies. All patients received Sotorasib at a dose of 960 mg orally once daily. The primary endpoint was the objective response rate (ORR).
Key Efficacy Results
- Objective Response Rate (ORR): 21%
- Disease Control Rate: 84%
- Median Progression-Free Survival (PFS): 4.0 months
- Median Overall Survival (OS): 6.9 months
While the ORR may seem modest, it represents a significant signal in a disease where later-line options are extremely limited and KRAS mutations were previously considered "undruggable."
Safety and Tolerability
Sotorasib demonstrated a favorable safety profile:
- Adverse Event Incidence: 42% of patients experienced treatment-related side effects.
- Grade 3+ Side Effects: Occurred in only 16% of patients.
- No treatment-related deaths were reported.
Conclusion
The authors concluded that Sotorasib monotherapy provides clinically meaningful antitumor activity with a manageable safety profile in patients with pretreated KRAS G12C-mutated advanced pancreatic cancer. These findings establish KRAS G12C as a viable therapeutic target in pancreatic cancer, similar to results seen in non-small cell lung cancer.
Source: The New England Journal of Medicine - Sotorasib in Pancreatic Cancer
#PancreaticCancer #KRASG12C #Sotorasib #Lumakras #CodeBreaK100 #PrecisionMedicine #CancerResearch
Vous envisagez des soins au Japon ? Besoin d’informations et d’aide ?
Nous vous aidons à rassembler les informations nécessaires pour un déplacement médical au Japon, à contacter les établissements japonais et à organiser une consultation de second avis.La première consultation est gratuite ; un conseiller vous aide à clarifier les prochaines étapes.
Figure 1
Figure 2
Figure 3
Figure 4